Results 241 to 250 of about 9,966 (258)
Some of the next articles are maybe not open access.
Propofol-associated serious adverse events: an analysis of the FAERS database
Biotechnology and Genetic Engineering Reviews, 2023Propofol is an ultra-fast-acting intravenous anesthetic, which is rapidly metabolized primarily into inactive compounds in the live and then excreted in the urine. The purpose of this study is to explore the risk signals of propofol based on the US FDA Adverse Event Reporting System database.
Guocheng, Xuan +4 more
openaire +2 more sources
An observational study on the safety of teprotumumab based on FAERS database
EndocrineTeprotumumab plays an important role in thyroid eye disease pathogenesis and progression. We intend to mine the adverse event (AE) signals from a relevant database, thereby contributing to the safe use of teprotumumab.The data obtained from the ASCII data packages in the FAERS database from January 2020 to the second quarter of 2023 were imported into ...
Xing-Long, Wang +3 more
openaire +2 more sources
Safety evaluation of ceftazidime/avibactam based on FAERS database
InfectionTo explore adverse event (AE) signals of Ceftazidime/avibactam (CZA) based on the FDA Adverse Event Reporting System (FAERS) database.AE reports primarily associated with CZA were retrieved from the FAERS database from the second quarter of 2015 to the second quarter of 2023.
Xiuhong, Zhang +6 more
openaire +2 more sources
Drug-induced hyperacusis: a disproportionality analysis of the FAERS database
Expert Opinion on Drug SafetyHyperacusis is a non-negligible clinical condition, but reports related to drug-induced hyperacusis are rare. The aim of this study was to investigate the risk of drug-induced hyperacusis and to identify the top drugs that can cause hyperacusis through the FAERS database.We used the search term 'hyperacusis' to query all reports of hyperacusis in the ...
HuaJie, Lin +3 more
openaire +2 more sources
Adverse events associated with Atogepant: a FAERS-based pharmacovigilance analysis
Expert Opinion on Drug SafetyMigraine, a prevalent neurovascular disorder, can significantly disrupt an individual's daily life. Atogepant (AGN-241689), an orally administered small-molecule drug classified as a calcitonin gene-related peptide receptor antagonist, is utilized for prophylactic migraine treatment.
Ying Zhang, Shengzhu Sun, Yuming Wang
openaire +2 more sources
Antidepressants and cataract: A disproportionality analysis of the FAERS database
European Neuropsychopharmacology, 2019Spyridon Siafis +2 more
openaire +2 more sources
Leading FAER Into the Future: Seeking Candidates for FAER President and CEO
ASA Monitor, 2015openaire +1 more source